{"id":20626,"date":"2023-03-23T17:50:00","date_gmt":"2023-03-23T09:50:00","guid":{"rendered":"https:\/\/flcube.com\/?p=20626"},"modified":"2025-01-06T17:56:06","modified_gmt":"2025-01-06T09:56:06","slug":"biohaven-acquires-global-rights-for-dual-tyk2-jak1-inhibitor-bhv-8000-from-highlightll","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=20626","title":{"rendered":"Biohaven Acquires Global Rights for Dual TYK2\/JAK1 Inhibitor BHV-8000 from Highlightll"},"content":{"rendered":"\n<p>US-based Biohaven Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/BHVN:NYSE\">NYSE: BHVN<\/a>) has announced the acquisition of global rights, excluding China regions, for the development of an oral, brain-penetrant, dual inhibitor of Tyrosine Kinase 2 (TYK2) and Janus Kinase 1 (JAK1) for the treatment of brain disorders. The compound, BHV-8000 (previously TLL-041), was licensed from Hangzhou Highlightll Pharmaceutical Co. Ltd. Biohaven plans to advance the agent into a Phase I study in 2023.<\/p>\n\n\n\n<p><strong>Financial Terms and Development Coordination<\/strong><br>Under the terms of the agreement, Highlightll will receive USD 10 million in upfront cash and USD 10 million in BHVN equity, along with development and commercial milestone payments of up to USD 950 million, and tiered royalty payments ranging from mid-single digit to lower teens percentages. Biohaven and Highlightll will coordinate clinical development across global regions.<\/p>\n\n\n\n<p><strong>Mechanism and Potential of BHV-8000<\/strong><br>BHV-8000 is a highly selective, brain-penetrant, dual TYK2\/JAK1 inhibitor. TYK2 and JAK1 are STAT pathway activators that address a range of proinflammatory cytokines. Inhibiting these kinases may play a significant role in reducing inflammation in neurological disorders, including Parkinson&#8217;s disease, Alzheimer&#8217;s disease, amyotrophic lateral sclerosis, and multiple sclerosis. BHV-8000 has demonstrated high selectivity over JAK2, JAK3, and other kinases, potentially offering improved safety over less selective or non-selective JAK inhibitors. Mechanistic proof of concept for BHV-8000 has been demonstrated in multiple preclinical models.<\/p>\n\n\n\n<p><strong>About Hangzhou Highlightll and Biohaven<\/strong><br>Hangzhou Highlightll is an innovative drug development company focused on the research and development of small molecules for the treatment of autoimmune\/inflammatory diseases and central nervous system diseases. BHV-8000 is the company&#8217;s lead project, a peripheral TYK2\/JAK1 dual inhibitor being evaluated in clinical trials in the US and China for immunological disorders.<\/p>\n\n\n\n<p>Biohaven is a global clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing life-changing therapies for people with debilitating neurological and neuropsychiatric diseases, including rare disorders. In October 2022, Pfizer acquired Biohaven&#8217;s migraine drug rimegepant and related pipeline candidates in a deal worth USD 11.6 billion.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>US-based Biohaven Ltd. (NYSE: BHVN) has announced the acquisition of global rights, excluding China regions,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[3044,3045],"class_list":["post-20626","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-biohaven","tag-nyse-bhvn"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Biohaven Acquires Global Rights for Dual TYK2\/JAK1 Inhibitor BHV-8000 from Highlightll - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based Biohaven Ltd. (NYSE: BHVN) has announced the acquisition of global rights, excluding China regions, for the development of an oral, brain-penetrant, dual inhibitor of Tyrosine Kinase 2 (TYK2) and Janus Kinase 1 (JAK1) for the treatment of brain disorders. The compound, BHV-8000 (previously TLL-041), was licensed from Hangzhou Highlightll Pharmaceutical Co. Ltd. Biohaven plans to advance the agent into a Phase I study in 2023.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=20626\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biohaven Acquires Global Rights for Dual TYK2\/JAK1 Inhibitor BHV-8000 from Highlightll\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=20626\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-23T09:50:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-06T09:56:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20626#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20626\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Biohaven Acquires Global Rights for Dual TYK2\\\/JAK1 Inhibitor BHV-8000 from Highlightll\",\"datePublished\":\"2023-03-23T09:50:00+00:00\",\"dateModified\":\"2025-01-06T09:56:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20626\"},\"wordCount\":334,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biohaven\",\"NYSE: BHVN\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20626#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20626\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=20626\",\"name\":\"Biohaven Acquires Global Rights for Dual TYK2\\\/JAK1 Inhibitor BHV-8000 from Highlightll - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-03-23T09:50:00+00:00\",\"dateModified\":\"2025-01-06T09:56:06+00:00\",\"description\":\"US-based Biohaven Ltd. (NYSE: BHVN) has announced the acquisition of global rights, excluding China regions, for the development of an oral, brain-penetrant, dual inhibitor of Tyrosine Kinase 2 (TYK2) and Janus Kinase 1 (JAK1) for the treatment of brain disorders. The compound, BHV-8000 (previously TLL-041), was licensed from Hangzhou Highlightll Pharmaceutical Co. Ltd. Biohaven plans to advance the agent into a Phase I study in 2023.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20626#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20626\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20626#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biohaven Acquires Global Rights for Dual TYK2\\\/JAK1 Inhibitor BHV-8000 from Highlightll\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biohaven Acquires Global Rights for Dual TYK2\/JAK1 Inhibitor BHV-8000 from Highlightll - Insight, China&#039;s Pharmaceutical Industry","description":"US-based Biohaven Ltd. (NYSE: BHVN) has announced the acquisition of global rights, excluding China regions, for the development of an oral, brain-penetrant, dual inhibitor of Tyrosine Kinase 2 (TYK2) and Janus Kinase 1 (JAK1) for the treatment of brain disorders. The compound, BHV-8000 (previously TLL-041), was licensed from Hangzhou Highlightll Pharmaceutical Co. Ltd. Biohaven plans to advance the agent into a Phase I study in 2023.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=20626","og_locale":"en_US","og_type":"article","og_title":"Biohaven Acquires Global Rights for Dual TYK2\/JAK1 Inhibitor BHV-8000 from Highlightll","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=20626","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-03-23T09:50:00+00:00","article_modified_time":"2025-01-06T09:56:06+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=20626#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=20626"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Biohaven Acquires Global Rights for Dual TYK2\/JAK1 Inhibitor BHV-8000 from Highlightll","datePublished":"2023-03-23T09:50:00+00:00","dateModified":"2025-01-06T09:56:06+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=20626"},"wordCount":334,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biohaven","NYSE: BHVN"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=20626#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=20626","url":"https:\/\/flcube.com\/?p=20626","name":"Biohaven Acquires Global Rights for Dual TYK2\/JAK1 Inhibitor BHV-8000 from Highlightll - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-03-23T09:50:00+00:00","dateModified":"2025-01-06T09:56:06+00:00","description":"US-based Biohaven Ltd. (NYSE: BHVN) has announced the acquisition of global rights, excluding China regions, for the development of an oral, brain-penetrant, dual inhibitor of Tyrosine Kinase 2 (TYK2) and Janus Kinase 1 (JAK1) for the treatment of brain disorders. The compound, BHV-8000 (previously TLL-041), was licensed from Hangzhou Highlightll Pharmaceutical Co. Ltd. Biohaven plans to advance the agent into a Phase I study in 2023.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=20626#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=20626"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=20626#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Biohaven Acquires Global Rights for Dual TYK2\/JAK1 Inhibitor BHV-8000 from Highlightll"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20626","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20626"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20626\/revisions"}],"predecessor-version":[{"id":20628,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20626\/revisions\/20628"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20626"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20626"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20626"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}